Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
Am J Med. 2020 Oct;133(10):1209-1218. doi: 10.1016/j.amjmed.2020.03.010. Epub 2020 Apr 7.
Chronic opioid use and dependence is common in patients with chronic pancreatitis. Patients with acute pancreatitis are frequently treated with opioids, but their risk for ongoing use is not well known. The aim of our study is to characterize opioid use in patients after an episode of acute pancreatitis and to assess persistent, chronic, and daily opioid use in such patients in the absence of chronic pancreatitis.
This is a single-center review of prospectively enrolled patients with acute pancreatitis. Using the Massachusetts Prescription Awareness Tool, we recorded all opioid prescriptions (ie, frequency, duration, and amount) for patients from December 2016 to September 2019, after index hospitalization for acute pancreatitis. Patients with chronic pancreatitis were excluded. We used univariate and multivariate analysis to determine predictors of opioid use at discharge and subsequent follow-up over 18 months.
Of 235 enrolled patients who were opioid-naïve, 123 patients (52.3%) received opioids at discharge after index hospitalization. In follow-up over 18 months, 40 patients (17.0%) received additional opioid prescriptions. These patients had more severe disease, longer length of stay, and higher pain score at discharge. Patients with prior history of acute pancreatitis, local complications, and higher pain scores were twice as likely to subsequently be prescribed opioids. Persistent opioid use was seen only in recurrent acute pancreatitis. There was no daily or chronic opioid use.
In the absence of chronic pancreatitis, there was no daily or chronic use of opioids in patients with acute pancreatitis. Persistent use was only seen in patients with recurrent acute pancreatitis. These patients are at increased risk of chronic opioid use and dependence.
慢性阿片类药物使用和依赖在慢性胰腺炎患者中很常见。急性胰腺炎患者经常接受阿片类药物治疗,但他们持续使用的风险尚不清楚。我们研究的目的是描述急性胰腺炎发作后患者的阿片类药物使用情况,并评估在没有慢性胰腺炎的情况下此类患者持续、慢性和每日使用阿片类药物的情况。
这是一项对前瞻性纳入的急性胰腺炎患者进行的单中心回顾性研究。使用马萨诸塞州处方意识工具,我们记录了 2016 年 12 月至 2019 年 9 月索引住院治疗急性胰腺炎后所有患者的阿片类药物处方(即频率、持续时间和数量)。排除慢性胰腺炎患者。我们使用单变量和多变量分析来确定出院时和随后 18 个月随访期间使用阿片类药物的预测因素。
在 235 名接受调查的阿片类药物初治患者中,有 123 名(52.3%)在索引住院治疗急性胰腺炎后出院时接受了阿片类药物治疗。在 18 个月的随访中,有 40 名患者(17.0%)接受了额外的阿片类药物处方。这些患者的病情更严重,住院时间更长,出院时疼痛评分更高。有急性胰腺炎既往史、局部并发症和更高疼痛评分的患者随后开阿片类药物的可能性增加一倍。仅在复发性急性胰腺炎患者中观察到持续性阿片类药物使用。没有每日或慢性阿片类药物使用。
在没有慢性胰腺炎的情况下,急性胰腺炎患者没有每日或慢性使用阿片类药物。仅在复发性急性胰腺炎患者中观察到持续性使用。这些患者有慢性阿片类药物使用和依赖的风险增加。